Hyphens Pharma International Launches Cerapro MED Skin Barrier Cream in Four European Markets
MT Newswires11-06 12:32
Hyphens Pharma International (SGX:1J5) has launched its Cerapro MEDz Skin Barrier Cream in Switzerland, Austria, Belgium and the Netherlands through Louis Widmer, which markets it as remederm Cerapro MED Skin Barrier Cream, according to a Thursday filing to the Singapore bourse.
Cerapro MED is a non-steroidal cream for the treatment of atopic dermatitis, CE-marked under the European Medical Device Regulation.
The launch follows the licensing, supply and commercialization agreement between the two companies in January.
Louis Widmer will market Cerapro MED to atopic dermatitis specialists, including dermatologists, paediatricians and allergists, as well as pharmacists.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
